Sage Journals: Discover world-class research

Abstract

Background:

Previous research characterizing factors influencing multiple sclerosis (MS) disease progression has typically been based on time to disease milestones (Kaplan–Meier, Cox hazard regression, etc.). A limitation of these methods is the handling of the often large groups of patients not reaching the milestone.

Objective:

To characterize clinical factors influencing MS disease progression as annual transitions from each Expanded Disability Status Scale (EDSS).

Method:

The annual progression of 11,964 patients from the Swedish MS Registry was analysed with 10 multinomial logistic regressions, that is, one for transition from each full EDSS with explanatory variables age, sex, age at onset, time in current EDSS, highest prior EDSS, MS course and treatment.

Results:

All factors (except sex) investigated had statistically significant impacts on transitions from at least one EDSS. However, significance and size of the effect are dependent on the EDSS state of the patient. Greater age, longer time in a state, highest prior EDSS, having progressive MS and treatment had significant impacts, whereas age at onset had minor impact.

Conclusion:

Our study confirms that established factors associated with MS disease worsening in time to disease milestones also have impacts on annual progression. This approach adds granularity to what EDSS these factors have an influence.

Keywords

Multiple sclerosis EDSS score clinical disease progression multinomial logistic regression

Get full access to this article

View all access options for this article.

References

Confavreux

Vukusic

The clinical course of multiple sclerosis. Handb Clin Neurol 2014; 122: 343–369.

Trojano

Pellegrini

Paolicelli

et al . Real-life impact of early interferon beta therapy in relapsing multiple sclerosis. Ann Neurol 2009; 66(4): 513–520.

Healy

Engler

Glanz

et al . Assessment of definitions of sustained disease progression in relapsing-remitting multiple sclerosis. Mult Scler Int 2013; 2013: 189624.

Tremlett

Zhao

Rieckmann

et al . New perspectives in the natural history of multiple sclerosis. Neurology 2010; 74(24): 2004–2015.

Confavreux

Age at disability milestones in multiple sclerosis. Brain 2006; 129(3): 595–605.

Runmarker

Andersen

Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up. Brain 1993; 116(Pt 1): 117–134.

Scalfari

Neuhaus

Degenhardt

et al . The natural history of multiple sclerosis: A geographically based study 10: Relapses and long-term disability. Brain 2010; 133(7): 1914–1929.

Manouchehrinia

Beiki

Hillert

Clinical course of multiple sclerosis: A nationwide cohort study. Mult Scler 2017; 23: 1488–1495.

Bove

McHenry

Hellwig

et al . Multiple sclerosis in men: Management considerations. J Neurol 2016; 263(7): 1263–1273.

10.

Jokubaitis

Spelman

Kalincik

et al . Predictors of disability worsening in clinically isolated syndrome. Ann Clin Transl Neurol 2015; 2(5): 479–491.

11.

Shirani

Zhao

Karim

et al . Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis. JAMA 2012; 308(3): 247–256.

12.

Greene

Econometric analysis. Upper Saddle River, NJ: Pearson Education, 2003.

13.

Andersen

From the Gothenburg cohort to the Swedish multiple sclerosis registry. Acta Neurol Scand Suppl 2012; 195: 13–19.

14.

Hillert

Stawiarz

The Swedish MS registry - clinical support tool and scientific resource. Acta Neurol Scand 2015; 132(Suppl. 199): 11–19.

15.

Lizrova Preiningerova

Novotna

Rusz

et al

Spatial and temporal characteristics of gait as outcome measures in multiple sclerosis (EDSS 0 to 6.5). J Neuroeng Rehabil 2015; 12(1): 14.

16.

Anderson

JA.

Regression and ordered categorical variables. J R Stat Soc Ser B 1984; 46(1): 1–30.

17.

Greenwood

Farewell

A comparison of regression models for ordinal data in an analysis of transplanted-kidney function. Can J Stat 1988; 16(4): 325–335.

18.

Noseworthy

Vandervoort

Wong

et al . Interrater variability with the Expanded Disability Status Scale (EDSS) and Functional Systems (FS) in a multiple sclerosis clinical trial. The Canadian Cooperation MS Study Group. Neurology 1990; 40(6): 971–975.

19.

Kappos

D’Souza

Lechner-Scott

et al . On the origin of Neurostatus. Mult Scler Relat Disord 2015; 4: 182–185.

20.

Meyer-Moock

Feng

Y-S

Maeurer

et al . Systematic literature review and validity evaluation of the Expanded Disability Status Scale (EDSS) and the Multiple Sclerosis Functional Composite (MSFC) in patients with multiple sclerosis. BMC Neurol 2014; 14: 58.

21.

Tedeholm

Skoog

Runmarker

et al . The risk of progression in ms depends on the features of preceding relapses: Application to first generation immunomodulating therapy. Neurology 2014; 82: 185.

22.

Minneboo

Jasperse

Barkhof

et al . Predicting short-term disability progression in early multiple sclerosis: Added value of MRI parameters. J Neurol Neurosurg Psychiatry 2008; 79(8): 917–923.

23.

Fisniku

Brex

Altmann

et al . Disability and T2 MRI lesions: A 20-year follow-up of patients with relapse onset of multiple sclerosis. Brain 2008; 131(3): 808–817.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.38 MB